



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Corrigendum

Corrigendum to “Structural modifications of *N*-arylamide oxadiazoles: Identification of *N*-arylpiperidine oxadiazoles as potent and selective agonists of CB₂” [Bioorg. Med. Chem. Lett. 18 (2008) 4267–4274]

Erin F. DiMauro^{a,*}, John L. Buchanan^a, Alan Chen^b, Renee Emkey^c, Stephen A. Hitchcock^f, Liyue Huang^d, Ming Y. Huang^e, Brett Janosky^d, Josie H. Lee^c, Xingwen Li^e, Matthew W. Martin^a, Susan A. Tomlinson^a, Ryan D. White^a, Xiao Mei Zheng^a, Vinod F. Patel^a, Robert T. Fremeau Jr.^e

^a Department of Medicinal Chemistry, Amgen Inc., One Kendall Square, Building 1000, Cambridge, MA 02139, USA

^b Department of Molecular Structure, Amgen Inc., One Kendall Square, Building 1000, Cambridge, MA 02139, USA

^c Department of HTS and Molecular Pharmacology, Amgen Inc., One Kendall Square, Building 1000, Cambridge, MA 02139, USA


^d Department of Pharmacokinetics & Drug Metabolism, Amgen Inc., One Kendall Square, Building 1000, Cambridge, MA 02139, USA

^e Department of Neuroscience, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA

^f Department of Medicinal Chemistry, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA


The authors regret that incorrect structures were included in Table 2 and Scheme 3. The correct structures appear below.
Table 2

Compound (±)-7
R:



Scheme 3

(±)-24



DOI of original article: [10.1016/j.bmcl.2008.06.096](https://doi.org/10.1016/j.bmcl.2008.06.096)

* Corresponding author. Tel.: +1 617 444 5189; fax: +1 617 621 3907.

E-mail address: edimauro@amgen.com (E.F. DiMauro).